文献速递泌尿男性生殖肿瘤

恩杂鲁胺治疗mCRPC中新发未确认骨病灶与结局的关联:PREVAIL与AFFIRM二次分析

Association Between New Unconfirmed Bone Lesions and Outcomes in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide: Secondary Analysis of the PREVAIL and AFFIRM Randomized Clinical Trials.
PubMed 文献 · JAMA Oncol · 2020-01-01

该研究为PREVAIL和AFFIRM两项III期随机试验的事后二次分析,纳入1672例恩杂鲁胺治疗的mCRPC男性,评估治疗后骨扫描新发未确认病灶与影像学无进展生存、总生存等结局的关联。结果显示在化疗初治人群中,新发未确认病灶与影像学无进展生存(HR 1.37,95%CI 0.81-2.30;而在多西他赛后人群中,新发未确认病灶与总生存缩短相关(HR 1.94,95%CI 1.10-3.44),但影像学无进展生存未显著降低(HR 1.21,95%CI 0.83-1.75;

要点

  • 化疗初治mCRPC中,恩杂鲁胺治疗后新发未确认骨病灶可能为假性进展,不提示不良结局。
  • 多西他赛后mCRPC中,新发未确认骨病灶与总生存缩短相关,可能代表真性进展。
  • 无论治疗背景,新发未确认骨病灶均未显著影响影像学无进展生存或生活质量。

核心结论

  • 在恩杂鲁胺治疗应答的mCRPC中,随访骨扫描新发未确认病灶可能代表假性进展,提示治疗应答良好。
  • 多西他赛后出现新发未确认骨病灶与更差总生存相关,可能代表真性进展。

研究设计与样本

  • PREVAIL和AFFIRM两项III期随机试验的事后回顾性二次分析,共纳入1672例恩杂鲁胺治疗的mCRPC男性。
  • 分析对象为恩杂鲁胺组中PSA下降或影像学稳定/软组织应答者,评估首次或第二次治疗后骨扫描新发未确认病灶的临床意义。

主要发现

  • PREVAIL中643例(中位年龄72岁,范围43-93岁),177例(27.5%)出现早/晚期未确认病灶;AFFIRM中404例(中位年龄70岁,范围41-88岁),73例(18.1%)出现。
  • 两种治疗背景下,生活质量随时间变化与是否存在新发未确认病灶无关。

临床怎么用

  • 化疗初治mCRPC患者恩杂鲁胺治疗后出现新发未确认骨病灶时,不应仅凭此提前停药,需结合PSA和软组织评估。
  • 多西他赛后mCRPC患者出现新发未确认骨病灶时,应警惕真性进展,考虑进一步功能影像学检查。

局限性

  • 为事后回顾性二次分析,可能存在选择偏倚和混杂因素。
  • 仅纳入恩杂鲁胺治疗应答者,结论不能推广至所有mCRPC患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: For men with metastatic castration-resistant prostate cancer (mCRPC) whose condition is responding to enzalutamide, new unconfirmed bone lesions detected at posttreatment scinitigraphy may reflect an osteoblastic reaction that represents healing, known as pseudoprogression, which can lead to premature discontinuation of therapy. OBJECTIVE: To determine the association between new unconfirmed lesions detected on a follow-up bone scintigram (bone scan) and outcomes in enzalutamide-treated men with mCRPC. DESIGN, SETTING, AND PARTICIPANTS: This post hoc, retrospective secondary analysis of 1672 enzalutamide-treated men from 2 phase 3, randomized mCRPC studies (PREVAIL and AFFIRM) before or after treatment with docetaxel was conducted from April 12, 2018, to July 25, 2019. Participants were men from the enzalutamide groups of the 2 studies with a decrease in prostate-specific antigen level at any time or with stable disease or soft-tissue disease responding to treatment based onradiologic findings. INTERVENTION: Enzalutamide, 160 mg once daily. MAIN OUTCOMES AND MEASURES: The clinical significance of new lesions detected on the first (early) or second (late) posttreatment bone scan, without an unfavorable change in prostate-specific antigen level or soft-tissue progression, was investigated. Associations of new unconfirmed lesions with radiographic progression-free survival, overall survival, decrease in prostate-specific antigen level, objective response in soft tissue, and quality of life were evaluated. RESULTS: Among the 643 men (median age, 72 years [range, 43-93 years]) in PREVAIL, early and late unconfirmed lesions were observed in 177 men (27.5%) with stable disease or disease responding to enzalutamide. Among the 404 men (median age, 70 years [range, 41-88 years]) in AFFIRM, early and late unconfirmed lesions were observed in 73 men (18.1%) with stable disease or disease responding to enzalutamide. In PREVAIL, men with new unconfirmed lesions had median radiographic progression-free survival (hazard ratio [HR], 1.37 [95% CI, 0.81-2.30]; P = .23) and median overall survival (HR, 1.25 [95% CI, 0.85-1.83]) in the chemotherapy-naive setting similar to men those of men without such new lesions. In AFFIRM, the median overall survival (HR, 1.94 [95% CI, 1.10-3.44]) was reduced among men with unconfirmed bone lesions, but the median radiographic progression-free survival was not reduced (HR, 1.21 [95% CI, 0.83-1.75]; P = .32). Quality of life over time was similar regardless of the presence of new unconfirmed lesions detected on a follow-up bone scan in either setting. CONCLUSIONS AND RELEVANCE: These results suggest that new unconfirmed lesions detected on follow-up bone scans may represent pseudoprogression in men with mCRPC and are indicative of a favorable treatment response to enzalutamide. The detection of new unconfirmed bone lesions in men with mCRPC that responded to treatment with enzalutamide after docetaxel appears to be associated with worse overall survival and may represent true progression, thus highlighting the need for improved functional bone metastasis imaging. TRIAL REGISTRATION: ClinicalTrials.gov Identifiers: NCT01212991 and NCT00974311.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Armstrong AJ, Al-Adhami M, Lin P, et al. Association Between New Unconfirmed Bone Lesions and Outcomes in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide: Secondary Analysis of the PREVAIL and AFFIRM Randomized Clinical Trials. JAMA Oncol. 2020. PMID: 31830211. doi:10.1001/jamaoncol.2019.4636

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。